Key result
PCSK9 inhibitors and lipoprotein-a emerge as evolving targets for cardiovascular risk management.
Key points are not available for this paper at this time.
International audience
No takes yet. Share an insight, caveat, or question.
Martinez et al. (2021) studied this question. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and lipoprotein(a) represent evolving targets in the assessment and management of cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: